IGC Pharma (IGC) Cost of Revenue (2010 - 2025)

IGC Pharma (IGC) has reported Cost of Revenue for 16 consecutive years, with $92000.0 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Cost of Revenue fell 57.01% year-over-year to $92000.0 in Q3 2025; TTM through Sep 2025 was $771000.0, a 48.84% increase from a year earlier, with the FY2026 full-year figure at $262000.0, down 59.82% from the prior year.
• Cost of Revenue was $92000.0 for Q3 2025 at IGC Pharma, down from $350000.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $350000.0 in Q2 2025 and troughed at $18000.0 in Q3 2021.
• A 5-year average of $128052.6 and a median of $103000.0 in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue sank 90.52% in 2021 and jumped 328.57% in 2023, its largest moves.
• Over 5 years, Cost of Revenue stood at $80000.0 in 2021, then surged by 187.5% to $230000.0 in 2022, then plunged by 69.13% to $71000.0 in 2023, then jumped by 115.49% to $153000.0 in 2024, then tumbled by 39.87% to $92000.0 in 2025.
• The last three Cost of Revenue figures came in at $92000.0 (Q3 2025), $350000.0 (Q2 2025), and $176000.0 (Q1 2025), per Business Quant data.